52 results on '"Gentry, P Robinan"'
Search Results
2. Updating the Biologically Based Dose Response Model for the Nasal Carcinogenicity of Inhaled Formaldehyde in the F344 Rat
3. Incorporation of rapid association/dissociation processes in tissues into the monkey and human physiologically based pharmacokinetic models for manganese
4. Relative contributions of endogenous and exogenous formaldehyde to formation of deoxyguanosine monoadducts and DNA-protein crosslink adducts of DNA in rat nasal mucosa
5. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate Implications of Human Variability
6. Considerations for a Biologically Based Risk Assessment for Arsenic
7. Time-dependent genomic response in primary human uroepithelial cells exposed to arsenite for up to 60 days
8. Physiologically Based Pharmacokinetic/Toxicokinetic Modeling
9. A Kinetic Analysis of DNA-Deoxy Guanine Adducts in the Nasal Epithelium Produced by Inhaled Formaldehyde in Rats—Assessing Contributions to Adduct Production From Both Endogenous and Exogenous Sources of Formaldehyde
10. Incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene
11. Extended Analysis and Evidence Integration of Chloroprene as a Human Carcinogen
12. Considerations for refining the risk assessment process for formaldehyde: Results from an interdisciplinary workshop
13. Updating physiologically based pharmacokinetic models for manganese by incorporating rapid association/dissociation processes in tissues
14. An evaluation of the USEPA Proposed Approaches for applying a biologically based dose-response model in a risk assessment for perchlorate in drinking water
15. Peak Exposures in Epidemiologic Studies and Cancer Risks: Considerations for Regulatory Risk Assessment
16. Dose-response for assessing the cancer risk of inorganic arsenic in drinking water: the scientific basis for use of a threshold approach
17. Physiologically-based pharmacokinetic modeling suggests similar bioavailability of Mn from diet and drinking water
18. Application of the adverse outcome pathway (AOP) approach to inform mode of action (MOA): A case study with inorganic arsenic
19. Quantitative risk assessment of tobacco products: A potentially useful component of substantial equivalence evaluations
20. Response to Dr. Bernard D. Goldstein’s Letter to the Editor
21. Six years after the NRC review of EPA's Draft IRIS Toxicological Review of Formaldehyde : Regulatory implications of new science in evaluating formaldehyde leukemogenicity
22. Formaldehyde, Hematotoxicity, and Chromosomal Changes—Letter
23. Evaluation of triclosan in Minnesota lakes and rivers: Part II - human health risk assessment
24. Does occupational exposure to formaldehyde cause hematotoxicity and leukemia-specific chromosome changes in cultured myeloid progenitor cells?
25. A tissue dose-based comparative exposure assessment of manganese using physiologically based pharmacokinetic modeling—The importance of homeostatic control for an essential metal
26. The need for transparency and reproducibility in documenting values for regulatory decision making and evaluating causality: The example of formaldehyde
27. Risk assessments for chronic exposure of children and prospective parents to ethylbenzene (CAS No. 100-41-4)
28. Evaluation of gene expression changes in human primary lung epithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide
29. The impact of recent advances in research on arsenic cancer risk assessment
30. Potential occupational risk of amines in carbon capture for power generation
31. Formaldehyde exposure and leukemia: Critical review and reevaluation of the results from a study that is the focus for evidence of biological plausibility
32. Evaluation of gene expression changes in human primary uroepithelial cells following 24-Hr exposures to inorganic arsenic and its methylated metabolites
33. Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate
34. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity
35. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: A progress report
36. Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose–response modeling in mice
37. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations
38. Comparison of Tissue Dosimetry in the Mouse Following Chronic Exposure to Arsenic Compounds
39. Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene
40. Data for Physiologically Based Pharmacokinetic Modeling in Neonatal Animals: Physiological Parameters in Mice and Sprague-Dawley Rats
41. Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry 2Current address: Novartis Pharmaceuticals, East Hanover, NJ 07936.
42. Interspecies Dose Extrapolation for Inhaled Dimethyl Sulfate: A PBPK Model-Based Analysis using Nasal Cavity N7-Methylguanine Adducts
43. Physiologically Based Pharmacokinetic Modeling of Arsenic in the Mouse
44. Evaluation of the Potential Impact of Age- and Gender-Specific Lung Morphology and Ventilation Rate on the Dosimetry of Vapors
45. Application of a Physiologically Based Pharmacokinetic Model for Reference Dose and Reference Concentration Estimation for Acetone
46. Evaluation of the Potential Impact of Age- and Gender-Specific Lung Morphology and Ventilation Rate on the Dosimetry of Vapors
47. A HYBRID COMPUTATIONAL FLUID DYNAMICS AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR COMPARISON OF PREDICTED TISSUE CONCENTRATIONS OF ACRYLIC ACID AND OTHER VAPORS IN THE RAT AND HUMAN NASAL CAVITIES FOLLOWING INHALATION EXPOSURE
48. Determination of a site-specific reference dose for methylmercury for fish-eating populations
49. Evaluation of the Uncertainty in an Oral Reference Dose for Methylmercury Due to Interindividual Variability in Pharmacokinetics
50. Requirements for a Biologically Realistic Cancer Risk Assessment for Inorganic Arsenic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.